05:09 AM EDT, 04/17/2026 (MT Newswires) -- Microsoft ( MSFT )-backed (MSFT) OpenAI said Thursday it introduced a specialized artificial intelligence model named GPT-Rosalind to support biology and drug discovery research.

Early adopters using the new platform in their research operations include Amgen ( AMGN ) , Moderna ( MRNA ) , and Thermo Fisher Scientific ( TMO ) , among others, the company said.

The technology is designed to accelerate early-stage scientific workflows by assisting researchers with evidence synthesis, hypothesis generation, and experimental planning, OpenAI said.

The software is currently available as a research preview for qualified domestic corporate clients only through a restricted access program, it said.